These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 7543174

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation.
    Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, Suciu-Foca N, Savage D, Alobeid B, Bhagat G, Colovai AI.
    Cytometry B Clin Cytom; 2013; 84(1):21-9. PubMed ID: 23027709
    [Abstract] [Full Text] [Related]

  • 23. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C, Hassan HT.
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [Abstract] [Full Text] [Related]

  • 24. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
    Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS.
    Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow.
    Delwel R, van Gurp R, Bot F, Touw I, Löwenberg B.
    Leukemia; 1988 Dec; 2(12):814-9. PubMed ID: 3199876
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
    Lewis NR, Pallis M, Russell NH.
    Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
    [Abstract] [Full Text] [Related]

  • 30. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [Abstract] [Full Text] [Related]

  • 31. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
    Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroell T, Pfister K, Schmetzer H.
    Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
    [Abstract] [Full Text] [Related]

  • 32. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S, Kurata M, Abe S, Onishi I, Kirimura S, Nashimoto M, Murayama T, Hidaka M, Kitagawa M.
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [Abstract] [Full Text] [Related]

  • 33. Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Correlation with blast differentiation in bone marrow.
    Chang CC, Eshoa C, Kampalath B, Shidham VB, Perkins S.
    Am J Clin Pathol; 2000 Nov; 114(5):807-11. PubMed ID: 11068557
    [Abstract] [Full Text] [Related]

  • 34. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.
    Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638
    [Abstract] [Full Text] [Related]

  • 35. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
    Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O.
    Cytometry B Clin Cytom; 2005 Mar 01; 64(1):18-27. PubMed ID: 15668952
    [Abstract] [Full Text] [Related]

  • 36. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
    Cascavilla N, Musto P, D'Arena G, Melillo L, Carella AM, Petrilli MP, Sanpaolo G, Carotenuto M.
    Haematologica; 1998 May 01; 83(5):392-7. PubMed ID: 9658721
    [Abstract] [Full Text] [Related]

  • 37. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression.
    Reuss-Borst MA, Bühring HJ, Schmidt H, Müller CA.
    Leukemia; 1994 Feb 01; 8(2):258-63. PubMed ID: 7508533
    [Abstract] [Full Text] [Related]

  • 38. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression.
    Bradbury DA, Zhu YM, Russell NH.
    Leuk Lymphoma; 1997 Jan 01; 24(3-4):221-8. PubMed ID: 9156652
    [Abstract] [Full Text] [Related]

  • 39. Detection of minimal residual disease in acute myeloid leukemia.
    Gerhartz HH, Schmetzer H.
    Leukemia; 1990 Jul 01; 4(7):508-16. PubMed ID: 1695705
    [Abstract] [Full Text] [Related]

  • 40. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies.
    Macedo A, Orfão A, Gonzalez M, Vidriales MB, López-Berges MC, Martínez A, San Miguel JF.
    Leukemia; 1995 Jun 01; 9(6):993-8. PubMed ID: 7596191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.